| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy;
Department of Pathology, Section of General Pathology, University of Verona, Verona, Italy;
Rega Institute, University of Leuven, Leuven, Belgium;
Section of General Pathology and Immunology, University of Brescia, Brescia, Italy;
¶
Section of General Pathology, University of Milan, Milan, Italy; and
||
BioXell, Milan, Italy
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
, a costimulator of DC function, inhibited its production. IL-10 also induced CCL18 secretion in blood myeloid DC. No CCL18 secretion was observed in blood plasmacytoid DC. The opposite pattern of regulation was observed for CCL20, a prototypic inflammatory chemokine. CCL18 was found to be a chemotactic factor for immature DC. Therefore, CCL18 may act as a chemotactic signal that promotes the colocalization of immature DC with naive T lymphocytes in an IL-10-dominated environment with the consequent generation of T regulatory cells. These characteristics suggest that CCL18 may be part of an inhibitory pathway devoted to limiting the generation of specific immune responses at peripheral sites. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
DC are not only potent initiators of immune responses, they also play an important regulatory role. DC can induce either a Th1 cytotoxic response or favor a Th2 humoral-polarized response (12, 13, 14). Furthermore, DC can function as tolerogenic cells in response to self or environmental Ags (5, 15, 16). Recent evidence indicates that the microenvironment (e.g., type of Ag, pathogen, and cytokines) present at the site of DC activation will determine the quality of the T cell response generated (17, 18, 19, 20).
Chemokines are a large family of chemotactic proteins that play a crucial role in regulating leukocyte composition in inflamed tissues (6, 8, 21, 22, 23). DC secrete high levels of several chemokines (24, 25). DC-derived chemokines are believed to contribute to the recruitment of precursor cells and immature DC at the peripheral sites of inflammation (6, 8, 22) and within the lymph nodes, where they play a role in T and B cell localization and the DC-T cell interaction (2, 8). Chemokine production is usually associated with DC maturation both in vitro and in vivo (24, 25, 26). However, a limited number of chemokines, such as macrophage-derived chemokine/CCL22, TARC/CCL17, and PARC/DC-CK1/macrophage inflammatory protein-4/CCL18, are secreted in a constitutive manner by both immature monocyte-derived DC and blood myeloid DC (24, 25, 27, 28, 29) (M. Vulcano, unpublished observations). Whereas several studies have investigated the up-regulation of CCL22 and CCL17 in maturing DC, the regulation and the role of CCL18 in DC biology are poorly understood. CCL18 is a chemokine active on naive T cells and B lymphocytes with no known receptor identified to date and no rodent homologues (28, 30, 31, 32, 33). CCL18 mRNA expression was reported in monocytes, DC, normal lung, pneumonitis-affected lungs, germinal centers of regional lymph nodes and tonsils, atherosclerotic plaques, inflamed liver, septic rheumatoid arthritis, and dermis of contact hypersensitivity patients (28, 30, 31, 33, 34, 35, 36, 37, 38). Recent work has identified CCL18 as the major chemokine produced by tumor-associated macrophages in ovarian carcinoma (39). The aim of this study was to investigate the regulation of CCL18 production at both the mRNA and protein levels in human DC at different stages of maturation. In addition, CCL18 chemotactic activity on DC migration was investigated. The results reported here outline a unique pattern of regulation for CCL18 in maturing DC, and we propose that this chemokine is an inhibitory signal in the control of the immune response.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The following reagents were used for tissue culture: pyrogen-free saline (S.A.L.F., Bergamo, Italy), RPMI 1640 (Biochrom, Berlin, Germany), and aseptically collected FCS (HyClone Laboratories, Logan, UT). All reagents contained <0.125 endotoxin units/ml, as checked by the Limulus amebocyte lysate assay (Microbiological Associates, Walkersville, MD). LPS from Escherichia coli strain 055:B5 (LPS) was obtained from Difco (Detroit, MI), and Staphylococcus aureus Cowan I (SAC) was purchased from Calbiochem (San Diego, CA). Inactivated influenza virus strain A/Moscow/10/99 was a gift from Dr. T. De Magistris (Istituto Superiore di Sanità, Rome, Italy). Candida albicans was obtained as previously described (40). Dexamethasone (Dex), PGE2, and 1,25-dihydroxyvitamin D3 (VitD3) were obtained from Sigma-Aldrich (St. Louis, MO). Human rGM-CSF was a gift from Novartis (Milan, Italy). Human IL-13 was a gift from Dr. A. Minty (Sanofi Elf Bio Recherches, Labège, France). Human TNF-
was obtained from BASF/Knoll (Ludwighafen, Germany). Human rIL-10 was purchased from Schering-Plough (Milan, Italy), and human rIFN- was obtained from Roussel-UCLAF (Paris, France). Neutralizing mAb against TNF- (B.154.2) and an isotype-matched control were provided by Dr. G. Trinchieri (Schering-Plough, Dardilly, France). Anti-IL-10 mAb (23738.11) was obtained from R&D Systems (Minneapolis, MN) and was used as previously described (41). Anti-TNF- and anti-IL-10 mAbs had undetectable endotoxin levels by the Limulus amebocyte lysate assay.
Monocyte-derived DC preparation
DC were generated as previously described (24). Briefly, highly enriched blood monocytes (>95% CD14+) were obtained from buffy coats (through the courtesy of the Centro Trasfusionale, Ospedale Civile Formalori, Magenta, Italy) by Ficoll (Biochrom) and Percoll gradients (Pharmacia Fine Chemicals, Uppsala, Sweden). Monocytes were cultured for 6 days at 1 x 106/ml in six-well tissue culture plates (Falcon; BD Biosciences, Franklin Park, NJ) in RPMI 1640 supplemented with 10% FCS, 50 ng/ml GM-CSF, and 20 ng/ml IL-13. Where indicated, DC were further cultured in the presence of 100 ng/ml LPS and 20 ng/ml TNF for 48 h or as otherwise specified. CD40 ligand (CD40L)-transfected J558L cells or mock-transfected control cells were cultured with DC at a 1:4 ratio. Incubation of DC with the J558L mock-transfected cells did not induce cell maturation or chemokine production (data not shown).
Peripheral blood DC purification and culture
PBMC were isolated from buffy coats by Ficoll gradient (Pharmacia Biotec, Uppsala, Sweden), and peripheral blood myeloid (M-DC) and plasmacytoid (P-DC) DC were magnetically sorted with BDCA-1 and BDCA-4 cell isolation kits (Miltenyi Biotec, Bergisch Gladblach, Germany), respectively, as previously described (42) to a purity of 95–98%. Blood M-DC and P-DC (2 x 104 cells/well) were cultured in 96-well plates (Costar, Cambridge, MA) in RPMI 1640 culture medium supplemented with 5% FCS, 2 mM L-glutamine, 50 µg/ml gentamicin, 1 mM sodium pyruvate, and 1% nonessential amino acids plus 1000 U/ml GM-CSF and 10 ng/ml IL-4 (BD PharMingen, San Diego, CA) or 20 ng/ml IL-3 (BD PharMingen), respectively. Where indicated, cells were stimulated with 10 ng/ml IL-10 or 1 µg/ml LPS, SAC (1/5000), CD40L-transfected J558L cells at a ratio of 4:1, 6 µg/ml CpG oligonucleotides 2006 (MGW Biotech, Ebersberg, Germany), and 20 ng/ml hemagglutinin-inactivated influenza virus strain A/Moscow/10/99. After 24 h of culture, supernatants were collected, and chemokine concentrations were measured by ELISA.
Northern blot analysis
DC total RNA was extracted by the guanidinium thiocyanate or TRIzol method, blotted, and hybridized as previously described (43). Probes were labeled using the Megaprime DNA labeling system (Amersham International, Little Chalfont, U.K.) with [32P]dCTP (3000 Ci/mmol; Amersham International). Membranes were prehybridized at 42°C in Hybrisol (Oncor, Gaithersburg, MD) and hybridized overnight with 1 x 106 cpm/ml 32P-labeled probe. Membranes were then washed three times with 2x SSC (1x SSC = 0.15 M NaCl and 0.015 M sodium citrate, pH 7.0) at room temperature for 10 min, twice with 2x SSC/1% SDS at 60°C for 20 min, and then with 0.1x SSC for 5 min before being autoradiographed using Kodak XAR-5 films (Eastman Kodak, Rochester, NY) and intensifier screen at -80°C. The CCL20-specific probe was obtained as previously described (44). The CCL18-specific probe was obtained by RT-PCR amplifying the full-length cDNA reported sequence (GenBank accession no. 4506830) with specific primers (sense, 5'-ATCATGAAGGGCCTTGCAGCTGC-3'; antisense, 5'-TCAGGCATTCAGCTTCAGGTCGC-3') and confirmed by sequencing.
ELISA
An in-house sandwich ELISA for CCL18 was developed by coating plates with polyclonal anti-human CCL18 Ab (R&D Systems, Abingdon, U.K.). A second polyclonal anti-human CCL18 Ab (PeproTech, Rocky Hill, NJ) was used to detect bound immunoreactivity (39). Similar results were obtained using CCL18/PARC Duoset kit (R&D Systems). CCL20 and IL-12(p75) were measured in the cell-free supernatants by ELISA, using specific Abs as described previously (24, 44).
RT-PCR
Total RNA was reverse transcribed to cDNA. Subsequently, the cDNAs obtained were PCR amplified using specific primer pairs for VitD3 receptor (sense, 5'-CATCGGCATGATGAAGGAGTT-3'; antisense, 5'-CATCATGTCTGAAGAGGTGATACAG-3'). The oligonucleotide primers used in RT-PCR experiments were designed on distinct exons to exclude an amplification of possible contaminating genomic DNA in the RNA samples. Amplification of 
-actin cDNA was also conducted as an internal control for the efficiency of RNA extraction and RT. PCR products were separated and visualized on an ethidium bromide-stained agarose gel.
Migration assay
DC migration was evaluated using a 48-well microchemotaxis chamber technique. Briefly, 27 µl of chemokine or control medium (RPMI 1640 with 1% FCS) was added to the lower wells of the chemotaxis chamber (Neuroprobe, Pleasanton, CA) (43). Fifty microliters of cell suspension (1.5 x 106/ml) were seeded in the upper chamber. The two compartments were separated by a 5-µm pore size polyvinylpyrrolidone polycarbonate filter (Neuroprobe). The chamber was incubated for 90 min at 37°C in a humidified atmosphere in the presence of 5% CO2. At the end of the incubation, filters were removed and stained, and five high power oil immersion fields (x1000) were counted per well. Results are expressed as the mean of three replicates ± SD of a single experiment representative with at least three independent donors.
Statistical analysis
Statistical significance between the experimental groups was determined using paired Student’s t test.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In the first set of experiments the kinetics of CCL18 production during DC maturation were investigated. Immature DC were washed, and maturation was induced using an optimal concentration (100 ng/ml) of LPS. As expected on the basis of previous work, immature DC release CCL18 in a constitutive manner (28, 31). Fig. 1 shows that CCL18 is released at high levels (387 ± 66 ng/106 cell, after 48-h incubation; n = 15), making this protein one of the most highly expressed chemokines by this cell type (24). LPS stimulation did not alter the levels of CCL18 secretion up to 8 h. Thereafter, LPS strongly suppressed CCL18 production (109 ± 21 ng/106 cells at 48 h; n = 15). The kinetics of chemokine secretion under both basal and stimulated conditions were paralleled by specific mRNA expression as detected by Northern blot analysis (data not shown and see below). Fig. 1 shows that CCL20, a proinflammatory chemokine active on memory T cells and immature DC (45, 46, 47, 48, 49) that was investigated in parallel experiments, was produced in a detectable manner only by LPS-stimulated DC. CCL20 became detectable after 8-h incubation, and its production increased linearly up to 48 h, reaching 1.7 ± 0.1 ng/106 DC (n = 4). In the same experimental conditions other inflammatory chemokines (CXCL8, CCL2, and CCL3) were also found to be up-regulated (data not shown).
|
(a proinflammatory cytokine), or CD40L-transfected cells (a T cell-derived signal). After 48 h of culture, DC maturation was assessed in all cultures as the percentage of CD83+ and DC-LAMP+ cells (always >85% and >80%, respectively; data not shown). Fig. 2 shows that both CD40L and LPS stimulated CCL20 expression, with TNF- being a marginal, if any, agonist for this chemokine. In contrast, all three maturation agents inhibited CCL18 production after 48 h of stimulation, although with different potencies: CD40L > LPS > TNF (71, 65, and 43% inhibition, respectively). mRNA levels, as evaluated by Northern blot analysis using specific probes, paralleled the chemokine protein expression (Fig. 2, top and bottom, lower panels). Down-regulation of CCL18 production during DC maturation was also observed when other pathogen-derived maturing agents (SAC, C. albicans, and influenza virus) were used (Table I). Maturation of DC is associated with TNF secretion (50). To assess the contribution of this potential autocrine loop in LPS- and CD40L-induced CCL18 inhibition, experiments were performed in the presence of a TNF--blocking mAb (51). Results obtained with three different donors showed no effect of the anti-TNF Ab on CCL18 production by both immature and mature DC (data not shown).
|
|
and IL-10
The maturation and function of DC are controlled by pro- and anti-inflammatory cytokines. For instance, IFN- is known to promote IL-12 production by mature DC, whereas IL-10 inhibits DC maturation and IL-12 production (4, 12, 52). IL-12 production by DC is pivotal to orient T cells to a Th1-polarized phenotype, whereas in the presence of IL-10, T cells with Th2/T regulatory functions are generated (20). Fig. 3A shows that reduced levels of CCL18 are secreted by immature DC in the presence of IFN- (46 and 56% inhibition (p < 0.01) at 24 and 48 h, respectively). The degree of the inhibition was almost comparable to that observed following LPS-induced maturation. No additive effect was observed when LPS and IFN- were used together. In contrast, IL-10 strongly increased CCL18 secretion. The effect was already apparent after 24 h of stimulation (60% increase over control) and was increased further after 48 h (Fig. 3B). Despite the fact that IL-10 is known to inhibit LPS function in phagocytic cells, including DC, IL-10 could not reverse LPS-induced inhibition of CCL18 production (Fig. 3B). In the same experimental conditions CCL20 expression was induced by IFN- and inhibited by IL-10 (data not shown) as previously reported (48).
|
Regulation of CCL18 secretion by inhibitors of DC maturation
The results obtained with IL-10 were extended to other drugs known to affect different aspects of DC maturation and function, such as VitD3, corticosteroids, and PGE2. VitD3 and Dex block DC maturation (e.g., CD83 expression and IL-12 production) and inhibit chemokine production (e.g., CCL22, CXCL8, and CCL2), (24, 53) (M. Vulcano, unpublished observations). On the other hand, PGE2 does not affect the acquisition of a mature DC phenotype, but does inhibit IL-12 production (54).
Similar to the observations with IL-10, VitD3 did not modify LPS-induced inhibition of CCL18 production. However, in the absence of a maturation signal, VitD3 induced CCL18 production in a dose-dependent manner (Fig. 4A). The effect was already evident at 10-9 M (p < 0.05) and peaked at 10-7 M (p < 0.01) VitD3 (data not shown). The expression of VitD3 receptors was equally well observed in immature and mature DC by PCR analysis (Fig. 4B). It must be noted that a certain degree of donor-to-donor variability was observed in these experiments; some donors (three of seven) were only weakly responsive to the effect of the drug (data not shown). The reason for this variability is currently under investigation. Under the same culture conditions VitD3 partially (40%) inhibited CCL20 release by LPS-stimulated DC (Fig. 4A) as well as the release of CCL22 (24) (data not shown).
|
55% (n = 4; Fig. 5A). A similar degree of inhibition was observed when DC were cultured with either LPS or CD40L regardless of the presence of the two inhibitors (Fig. 5A). Although both Dex and PGE2 had a negative effect on DC maturation and IL-12 production (Fig. 5B), these treatments did not reverse maturation-induced inhibition of CCL18 release. Parallel experiments showed that CCL20 production in LPS-stimulated DC was inhibited in the presence of PGE2, whereas it was resistant to the effect of Dex (data not shown) as previously reported (55). As expected, Dex, PGE2, and VitD3 under the experimental conditions used blocked in a similar manner (>80%) IL-12 production by DC cultured with LPS or CD40L (Fig. 5B and data not shown).
|
The studies on CCL18 production were extended to circulating DC subsets. Neither M-DC nor P-DC produced CCL18 in a constitutive manner; following in vitro culture with a number of maturing agonists, including LPS, SAC, influenza virus, CpG, and CD40L; or in the presence of VitD3 (data not shown). However, in agreement with the results obtained with monocyte-derived DC, IL-10 was able to selectively up-regulate CCL18 production in M-DC, with 19 ± 4 and 103 ± 17 ng/106 M-DC after 24- and 48-h culture, respectively (n = 3). On the contrary, no CCL18 production was observed by IL-10-stimulated P-DC (data not shown).
Migration of immature DC to CCL18
Finally, the ability of CCL18 to induce chemotaxis of DC was investigated. Fig. 6 shows that CCL18 was able to induce chemotaxis of immature DC with a bell-shaped dose-response curve. At the peak of chemotactic response the number of migrated DC was similar to that observed in the presence of an optimal concentration of CCL3 (43). Because the optimal CCL18 concentration slightly varied (between 100 and 300 ng/ml) using two different commercially available CCL18 preparations, results were confirmed using natural purified CCL18 (39). Fig. 6 shows that natural CCL18 was also active as a chemotactic agonist for immature DC, with an optimal concentration of 100 ng/ml. No migration of mature DC was induced by any of the three CCL18 preparations, indicating that the still unknown CCL18 receptor must be inactivated/down-regulated during the DC maturation process (data not shown).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
CCL18 is released at high levels by immature DC (387 ± 66 ng/106 DC in 48 h). Therefore, CCL18, together with CCL22, CCL17, and CXCL8, represents one of the most abundantly secreted chemokines by DC (24, 25). CCL18 inhibition was detectable after 8 h and was observed with all maturation agonists used (i.e., LPS, TNF, CD40L, SAC, C. albicans, and influenza virus) and in the presence of IFN-, a costimulator of DC functions (12). Previous studies performed by RT-PCR reported a limited induction of CCL18 mRNA in 24-h LPS-stimulated DC (25). However, in the present study the decrease in CCL18 protein secretion was paralleled by the inhibition of CCL18 mRNA levels, as evaluated by Northern blot, a more quantitative analysis than RT-PCR. The reason for this discrepancy is at present uncertain. To our knowledge, this is a unique feature, since only one other chemokine, CXCL13, was shown to be selectively inhibited at the mRNA level by CD40L, but not by LPS or TNF stimulation (60). Incubation of immature DC with Dex and PGE2 also resulted in a partial decrease in CCL18 secretion. The blocked acquisition of the DC mature phenotype by these two agents did not reverse CCL18 inhibition. Conversely, up-regulation of CCL18 secretion by immature DC was observed in the presence of VitD3 and IL-10, two known suppressors of DC maturation and function (52, 53). VitD3 is an immunosuppressive agent active in autoimmune diseases and graft rejection models by inhibiting Ag-induced T cell proliferation, cytokine production, and Th1 development (61, 62). IL-10 is an anti-inflammatory cytokine produced in a constitutive way at the mucosal sites and involved in the inhibition of inflammatory and immune reactions in many pathological conditions, including tumors (63). It is interesting to note that Dex was reported to enhance IL-4-induced expression of CCL18 in human monocytes (31). In the same experimental system CCL18 was induced by IL-10. CCL18 was recently identified as the most abundant chemokine in human ovarian ascites. CCL18 was produced by tumor-associated macrophages, very likely in response to tumor- and macrophage-derived IL-10 (39). The regulation of CCL18 production in DC reported in this study strengthens the concept that CCL18 is a mediator of the alternative activated (or type II) APC response (64). Cytokines and drugs associated with polarized type II responses (e.g., IL-4, IL-10, corticosteroids, and VitD3) induce an alternative activation program with distinct functional properties. These functionally polarized cells play a key role in the subversion of adaptive immunity and in inflammatory circuits that promote tolerance and tumor progression (65).
There is evidence that stimulation of naive T lymphocytes with immature DC induces the generation of IL-10-producing T regulatory cells (20). Since CCL18 is chemotactic for both immature DC and naive T cells, CCL18 production by immature DC could promote the interaction of these two cell types. Finally, a recent study by Nibbs et al. (66) showed that CCL18, in addition to being a T cell chemoattractant, exhibits antagonist activity for CCR3, a chemotactic receptor for eosinophils and basophils. Taken together, these findings strongly suggest that at nonlymphoid sites CCL18 may not act as a proinflammatory chemokine, but, rather, it may represent a negative mechanism to limit the onset of immune reactions. CCL18 antagonistic activity for CCR3 may serve to antagonize local production of proallergic chemokines. Furthermore, the recruitment of naive T cells by immature DC may favor a tolerogenic condition. However, in the presence of a severe inflammatory situation, DC will be induced to mature with the consequent down-regulation of CCL18 production. This CCL18 homeostatic function might be increased in the presence of immunosuppressive, anti-inflammatory cytokines, such as IL-10, or during immunosuppressive pharmacological treatments, as in the case of VitD3 or corticosteroid administration. Therefore, CCL18 production by immature DC could be part of a default strategy to limit the uncontrolled generation of inflammatory reactions. Unfortunately, CCL18 was generated by the fusion of two macrophage inflammatory protein-1-like genes, an event that happened late in evolution (32, 33). No rodent CCL18 exists, and this makes it impossible to test this hypothesis in an in vivo experimental model. In conclusion, chemokines, like other proinflammatory cytokines, possess strategies to limit their own inflammatory potential (67). This goal is exploited by alternative strategies, such as the production of chemokines with antagonist activity (66, 68, 69), the generation of structural decoy chemokine receptors (67), or the production of chemokines, such as CCL18, that are able to limit the onset of an immune response.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Silvano Sozzani, Istituto di Ricerche Farmacologiche Mario Negri, via Eritrea 62, 20157 Milan, Italy. E-mail address: sozzani{at}marionegri.it
3 Abbreviations used in this paper; DC, dendritic cell; CD40L, CD40 ligand; Dex, dexamethasone; M-DC, myeloid DC; P-DC, plasmacytoid DC; SAC, Staphylococcus aureus Cowan I; VitD3, vitamin D3.
Received for publication August 29, 2002. Accepted for publication February 3, 2003.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
/LD78 and chemotactic for T lymphocytes, but not for monocytes. J. Immunol. 159:1140.[Abstract]
with a Th2-associated expression pattern. J. Immunol. 160:1411./LD78-like genes. Genomics 55:353.[Medline]
and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells. Int. J. Clin. Lab. Res. 27:118.[Medline]
(MIP-3)/CCL20 and MIP-3/CCL19. Eur. J. Immunol. 31:1981.[Medline]
from lung dendritic cells. J. Exp. Med. 186:825. and is highly expressed in human dendritic cells. J. Exp. Med. 186:837. and MIP-3. J. Immunol. 158:1033.[Abstract]
. J. Immunol. 162:186. in mediating the production of IL-8 triggered by lipopolysaccharide. J. Exp. Med. 178:2207.,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164:2405./CCL20 by epidermal keratinocytes and its role in atopic dermatitis. Int. Immunol. 13:95.-chemokine macrophage inflammatory protein 4, a property strongly enhanced by an amino-terminal alanine-methionine swap. J. Immunol. 164:1488.This article has been cited by other articles:
|
|
 |
|
  L. Szeles, G. Keresztes, D. Torocsik, Z. Balajthy, L. Krenacs, S. Poliska, A. Steinmeyer, U. Zuegel, M. Pruenster, A. Rot, et al. 1,25-Dihydroxyvitamin D3 Is an Autonomous Regulator of the Transcriptional Changes Leading to a Tolerogenic Dendritic Cell Phenotype J. Immunol., February 15, 2009; 182(4): 2074 - 2083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-B. Kim, C.-K. Kim, K. Iijima, T. Kobayashi, and H. Kita Protein Microarray Analysis in Patients With Asthma: Elevation of the Chemokine PARC/CCL18 in Sputum Chest, February 1, 2009; 135(2): 295 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Elia, P. Cappello, M. Puppo, T. Fraone, C. Vanni, A. Eva, T. Musso, F. Novelli, L. Varesio, and M. Giovarelli Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile J. Leukoc. Biol., December 1, 2008; 84(6): 1472 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Li, T. Syrovets, S. Paskas, Y. Laumonnier, and T. Simmet Mature Dendritic Cells Express Functional Thrombin Receptors Triggering Chemotaxis and CCL18/Pulmonary and Activation-Regulated Chemokine Induction J. Immunol., July 15, 2008; 181(2): 1215 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ricciardi, A. R. Elia, P. Cappello, M. Puppo, C. Vanni, P. Fardin, A. Eva, D. Munroe, X. Wu, M. Giovarelli, et al. Transcriptome of Hypoxic Immature Dendritic Cells: Modulation of Chemokine/Receptor Expression Mol. Cancer Res., February 1, 2008; 6(2): 175 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Laborde, S. Vanzulli, M. Beigier-Bompadre, M. A. Isturiz, R. A. Ruggiero, M. G. Fourcade, A. C. Catalan Pellet, S. Sozzani, and M. Vulcano Immune Complexes Inhibit Differentiation, Maturation, and Function of Human Monocyte-Derived Dendritic Cells J. Immunol., July 1, 2007; 179(1): 673 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Dumitriu, M. E. Bianchi, M. Bacci, A. A. Manfredi, and P. Rovere-Querini The secretion of HMGB1 is required for the migration of maturing dendritic cells J. Leukoc. Biol., January 1, 2007; 81(1): 84 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wimmer, S. K. Khaldoyanidi, M. Judex, N. Serobyan, R. G. DiScipio, and I. U. Schraufstatter CCL18/PARC stimulates hematopoiesis in long-term bone marrow cultures indirectly through its effect on monocytes Blood, December 1, 2006; 108(12): 3722 - 3729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Cappello, T. Fraone, L. Barberis, C. Costa, E. Hirsch, A. R. Elia, C. Caorsi, T. Musso, F. Novelli, and M. Giovarelli CC-Chemokine Ligand 16 Induces a Novel Maturation Program in Human Immature Monocyte-Derived Dendritic Cells J. Immunol., November 1, 2006; 177(9): 6143 - 6151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. d. Nadai, A.-S. Charbonnier, C. Chenivesse, S. Senechal, C. Fournier, J. Gilet, H. Vorng, Y. Chang, P. Gosset, B. Wallaert, et al. Involvement of CCL18 in Allergic Asthma J. Immunol., May 15, 2006; 176(10): 6286 - 6293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Piqueras, J. Connolly, H. Freitas, A. K. Palucka, and J. Banchereau Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors Blood, April 1, 2006; 107(7): 2613 - 2618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Boven, M. Van Meurs, M. Van Zwam, A. Wierenga-Wolf, R. Q. Hintzen, R. G. Boot, J. M. Aerts, S. Amor, E. E. Nieuwenhuis, and J. D. Laman Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis Brain, February 1, 2006; 129(2): 517 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J A Hardin Dendritic cells: potential triggers of autoimmunity and targets for therapy Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv86 - iv90. [Full Text] [PDF]
|
|
|
|
|
|
M. Rimoldi, M. Chieppa, P. Larghi, M. Vulcano, P. Allavena, and M. Rescigno Monocyte-derived dendritic cells activated by bacteria or by bacteria-stimulated epithelial cells are functionally different Blood, October 15, 2005; 106(8): 2818 - 2826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Breckpot, J. Corthals, A. Bonehill, A. Michiels, S. Tuyaerts, C. Aerts, C. Heirman, and K. Thielemans Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response J. Leukoc. Biol., October 1, 2005; 78(4): 898 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. McIlroy, S. Tanguy-Royer, N. Le Meur, I. Guisle, P.-J. Royer, J. Leger, K. Meflah, and M. Gregoire Profiling dendritic cell maturation with dedicated microarrays J. Leukoc. Biol., September 1, 2005; 78(3): 794 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Vermaelen and R. Pauwels Pulmonary Dendritic Cells Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 530 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Schutyser, A. Richmond, and J. Van Damme Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes J. Leukoc. Biol., July 1, 2005; 78(1): 14 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. van der Voort, M. Kramer, E. Lindhout, R. Torensma, D. Eleveld, A. W. T. van Lieshout, M. Looman, T. Ruers, T. R. D. J. Radstake, C. G. Figdor, et al. Novel monoclonal antibodies detect elevated levels of the chemokine CCL18/DC-CK1 in serum and body fluids in pathological conditions J. Leukoc. Biol., May 1, 2005; 77(5): 739 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lindstedt, A. Schiott, A. Bengtsson, K. Larsson, M. Korsgren, L. Greiff, and C. A. K. Borrebaeck Genomic and functional delineation of dendritic cells and memory T cells derived from grass pollen-allergic patients and healthy individuals Int. Immunol., April 1, 2005; 17(4): 401 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T R D J Radstake, R van der Voort, M ten Brummelhuis, M de Waal Malefijt, M Looman, C G Figdor, W B van den Berg, P Barrera, and G J Adema Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors Ann Rheum Dis, March 1, 2005; 64(3): 359 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gunther, C. Bello-Fernandez, T. Kopp, J. Kund, N. Carballido-Perrig, S. Hinteregger, S. Fassl, C. Schwarzler, G. Lametschwandtner, G. Stingl, et al. CCL18 Is Expressed in Atopic Dermatitis and Mediates Skin Homing of Human Memory T Cells J. Immunol., February 1, 2005; 174(3): 1723 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Vulcano, S. Dusi, D. Lissandrini, R. Badolato, P. Mazzi, E. Riboldi, E. Borroni, A. Calleri, M. Donini, A. Plebani, et al. Toll Receptor-Mediated Regulation of NADPH Oxidase in Human Dendritic Cells J. Immunol., November 1, 2004; 173(9): 5749 - 5756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pivarcsi, M. Gombert, M.-C. Dieu-Nosjean, A. Lauerma, R. Kubitza, S. Meller, J. Rieker, A. Muller, L. Da Cunha, A. Haahtela, et al. CC Chemokine Ligand 18, An Atopic Dermatitis-Associated and Dendritic Cell-Derived Chemokine, Is Regulated by Staphylococcal Products and Allergen Exposure J. Immunol., November 1, 2004; 173(9): 5810 - 5817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Perrier, F. O. Martinez, M. Locati, G. Bianchi, M. Nebuloni, G. Vago, F. Bazzoni, S. Sozzani, P. Allavena, and A. Mantovani Distinct Transcriptional Programs Activated by Interleukin-10 with or without Lipopolysaccharide in Dendritic Cells: Induction of the B Cell-Activating Chemokine, CXC Chemokine Ligand 13 J. Immunol., June 1, 2004; 172(11): 7031 - 7042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Struyf, E. Schutyser, M. Gouwy, K. Gijsbers, P. Proost, Y. Benoit, G. Opdenakker, J. Van Damme, and G. Laureys PARC/CCL18 Is a Plasma CC Chemokine with Increased Levels in Childhood Acute Lymphoblastic Leukemia Am. J. Pathol., November 1, 2003; 163(5): 2065 - 2075. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
